Damora Therapeutics Inc (DMRA)

$25.51 -3.18 (-11.08%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 216,700
Avg Vol 199,884
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 7%
Beta N/A
Analysts Strong Buy
Price Target N/A
Latest News on DMRA
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

Feb 12, 2026, 4:01 PM EST - 26 days ago

Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

GLTO

Galecto Announces Pricing of $275 Million Underwritten Public Offering

Feb 10, 2026, 10:42 PM EST - 4 weeks ago

Galecto Announces Pricing of $275 Million Underwritten Public Offering

GLTO

Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 16, 2025, 5:00 PM EST - 3 months ago

Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GLTO

GLTO, MOVE: two penny stocks quadrupled today – but should you buy?

Nov 10, 2025, 1:08 PM EST - 4 months ago

GLTO, MOVE: two penny stocks quadrupled today – but should you buy?

GLTO MOVE

Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

Nov 10, 2025, 11:47 AM EST - 4 months ago

Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

GLTO

Galecto Announces Acquisition of Damora Therapeutics

Nov 10, 2025, 7:00 AM EST - 4 months ago

Galecto Announces Acquisition of Damora Therapeutics

GLTO

Galecto Reports Third Quarter 2025 Operating and Financial Results

Nov 6, 2025, 4:30 PM EST - 4 months ago

Galecto Reports Third Quarter 2025 Operating and Financial Results

GLTO

What's Going On With Nano-Cap Galecto Stock On Tuesday?

Oct 7, 2025, 1:05 PM EDT - 5 months ago

What's Going On With Nano-Cap Galecto Stock On Tuesday?

GLTO

Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble

Oct 7, 2025, 10:27 AM EDT - 5 months ago

Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble

GLTO

Galecto Reports Second Quarter 2025 Operating and Financial Results

Aug 5, 2025, 4:15 PM EDT - 7 months ago

Galecto Reports Second Quarter 2025 Operating and Financial Results

GLTO

Galecto Reports First Quarter 2025 Operating and Financial Results

May 8, 2025, 4:30 PM EDT - 10 months ago

Galecto Reports First Quarter 2025 Operating and Financial Results

GLTO

Galecto Reports Full-Year 2024 Financial Results

Mar 19, 2025, 4:45 PM EDT - 1 year ago

Galecto Reports Full-Year 2024 Financial Results

GLTO

Galecto to Participate in Upcoming Investor Conferences

Feb 6, 2025, 8:00 AM EST - 1 year ago

Galecto to Participate in Upcoming Investor Conferences

GLTO

Galecto Reports Third Quarter 2024 Financial Results

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Galecto Reports Third Quarter 2024 Financial Results

GLTO

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

GLTO

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Oct 7, 2024, 8:45 AM EDT - 1 year ago

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

GLTO

Galecto Announces Reverse Stock Split

Aug 28, 2024, 9:00 AM EDT - 1 year ago

Galecto Announces Reverse Stock Split

GLTO

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

May 1, 2024, 4:01 PM EDT - 2 years ago

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

GLTO

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Dec 21, 2023, 4:05 PM EST - 2 years ago

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

GLTO

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

GLTO

Galecto Announces Plans to Explore Strategic Alternatives

Sep 26, 2023, 4:01 PM EDT - 2 years ago

Galecto Announces Plans to Explore Strategic Alternatives

GLTO

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GALT GLTO

Galecto to Present at Investor Conferences in September

Aug 31, 2023, 11:00 AM EDT - 2 years ago

Galecto to Present at Investor Conferences in September

GLTO

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Aug 15, 2023, 8:39 AM EDT - 2 years ago

Galecto shares drop 65% as biotech halts development of lung-disease treatment

GLTO

Galecto to discontinue development of lung disease treatment

Aug 15, 2023, 7:55 AM EDT - 2 years ago

Galecto to discontinue development of lung disease treatment

GLTO

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Aug 15, 2023, 7:30 AM EDT - 2 years ago

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

GLTO

Galecto Reports Second Quarter Operating and Financial Results

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Galecto Reports Second Quarter Operating and Financial Results

GLTO

Galecto Set to Join Russell Microcap® Index

Jun 20, 2023, 8:58 AM EDT - 2 years ago

Galecto Set to Join Russell Microcap® Index

GLTO

Galecto to Present at the Upcoming Jefferies Healthcare Conference

May 30, 2023, 8:00 AM EDT - 3 years ago

Galecto to Present at the Upcoming Jefferies Healthcare Conference

GLTO

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

May 23, 2023, 8:30 AM EDT - 3 years ago

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

GLTO

Galecto to Present Poster at Upcoming ATS 2023 International Conference

May 17, 2023, 4:01 PM EDT - 3 years ago

Galecto to Present Poster at Upcoming ATS 2023 International Conference

GLTO

Galecto Reports First Quarter Operating and Financial Results

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Galecto Reports First Quarter Operating and Financial Results

GLTO

Galecto: Promising Pipeline And Excellent Risk-Reward

Apr 18, 2023, 7:01 PM EDT - 3 years ago

Galecto: Promising Pipeline And Excellent Risk-Reward

GLTO

Galecto to Present Two Posters at AACR Annual Meeting 2023

Apr 13, 2023, 8:30 AM EDT - 3 years ago

Galecto to Present Two Posters at AACR Annual Meeting 2023

GLTO

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Mar 9, 2023, 7:00 AM EST - 3 years ago

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

GLTO

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Mar 2, 2023, 4:05 PM EST - 3 years ago

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

GLTO

Galecto to Participate in SVB Securities Global Biopharma Conference

Feb 1, 2023, 8:00 AM EST - 3 years ago

Galecto to Participate in SVB Securities Global Biopharma Conference

GLTO

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Dec 7, 2022, 4:05 PM EST - 3 years ago

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

GLTO

Galecto Reports Third Quarter Operating and Financial Results

Nov 8, 2022, 9:15 AM EST - 3 years ago

Galecto Reports Third Quarter Operating and Financial Results

GLTO

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Nov 8, 2022, 6:00 AM EST - 3 years ago

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

GLTO

Galecto to Participate in Jefferies London Healthcare Conference

Nov 3, 2022, 8:00 AM EDT - 3 years ago

Galecto to Participate in Jefferies London Healthcare Conference

GLTO

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

GLTO

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Oct 19, 2022, 8:00 AM EDT - 3 years ago

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

GLTO

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Oct 17, 2022, 6:00 AM EDT - 3 years ago

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

GLTO

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

Sep 29, 2022, 10:11 AM EDT - 3 years ago

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

GLTO

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Sep 29, 2022, 6:00 AM EDT - 3 years ago

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

GLTO

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

GLTO

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Aug 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

GLTO

Galecto to Participate at Jefferies Healthcare Conference

May 31, 2022, 8:30 AM EDT - 4 years ago

Galecto to Participate at Jefferies Healthcare Conference

GLTO

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

May 26, 2022, 8:30 AM EDT - 4 years ago

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

GLTO